Clinical trial
Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury
NCT01509885 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury
- Lead sponsor
- University of Alberta
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2010
- Completion date
- November 30, 2012
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.